The Food and Drug Administration is seeking public feedback on a discussion paper released today on potential regulatory approaches for generative artificial intelligence-enabled medical devices. The paper includes considerations for risk assessment, premarket evaluation, post-market monitoring and other areas. The agency intends to gather early stakeholder input and advance broader discussion on policy frameworks for generative AI. The FDA said comments must be submitted by Oct. 19.  

Headline
An FBI report released Nov. 13 details actions by cyber actors weaponizing ARTEX, an open-source, large language model-driven agentic artificial intelligence…
Headline
The AHA will host a webinar Dec. 1 at 1 p.m. ET on how to create and build an effective artificial intelligence training program. Attendees will learn how to…
Headline
A Gallup survey published Nov. 9 on patient comfort with artificial intelligence in care found that 56% of U.S. adults who visited a primary care provider in…
Headline
The Food and Drug Administration is seeking feedback on a discussion paper released Nov. 6 on the benefits and risks of robotic medical devices with autonomous…
Headline
Christine Moutier, M.D., chief medical officer at the American Foundation for Suicide Prevention, discusses the usage of artificial intelligence chatbots among…
Headline
Christine Moutier, M.D., chief medical officer at the American Foundation for Suicide Prevention, discusses the usage of artificial intelligence chatbots among…